Adocia Stock: price and insider trades · France

Adocia’s portfolio spans several strategic programs. In diabetes, BioChaperone Lispro is an ultra-rapid insulin formulation intended to improve glycemic control. The company retains development rights in many territories, including the United States, Europe, Japan, and Latin America. Adocia is also developing next-generation peptide combinations for obesity, particularly GLP-1 / amylin combinations, as well as AdOral Sema, an oral semaglutide formulation. Other programs such as M1Pram and AdoXLong reflect the company’s ambition to broaden its pipeline with more convenient, longer-acting, or more differentiated treatment options.

From an operational and geographic standpoint, Adocia remains a mid-sized biotech centered in Lyon but oriented toward global markets through partnerships. The company has signed licensing or collaboration agreements with international pharmaceutical players, which is consistent with its strategy of monetizing innovation after clinical validation. In 2025-2026, Adocia strengthened its financial structure through several fundraising transactions and stated that its cash position and recent financing extend its funding horizon to the beginning of Q2 2027. This combination of breakthrough science, a focused metabolic pipeline, and international partnering makes Adocia a notable French biotech name in the diabetes and obesity space.